The ccr6 antagonists market is projected to grow from USD 1.0 billion in 2026 to USD 3.1 billion by 2036, at a CAGR of 12.0%. Small-molecule CCR6 inhibitors will dominate with a 61.0% market share, while autoimmune diseases will lead the applications segment with a 66.0% share.